Filing Flows › Comparisons › BEAM vs ATYR
Beam Therapeutics vs aTYR Pharma: BEAM and ATYR compared
Beam Therapeutics is the larger company: $307K of revenue in its latest quarter (Q3 2026) against $190K for aTYR Pharma (Q3 2025).
Where the money goes: BEAM and ATYR
Beam Therapeutics (BEAM) · Q3 2026
Beam Therapeutics, Q3 2026: revenue $307K (-97% year over year), net loss $134M, operating cash flow −$111M. The chart follows the revenue to costs, profit and cash.
aTYR Pharma (ATYR) · Q3 2025
aTYR Pharma, Q3 2025: revenue $190K, net loss $25.7M, operating cash flow −$20.5M. The chart follows the revenue to costs, profit and cash.
| Beam Therapeutics (BEAM) | aTYR Pharma (ATYR) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2025 |
| Revenue | $307K | $190K |
| Revenue growth, Y/Y | -97% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$134M | −$25.7M |
| Operating cash flow | −$111M | −$20.5M |
Questions
Which is bigger, Beam Therapeutics or aTYR Pharma?
Beam Therapeutics is the larger company: $307K of revenue in its latest quarter (Q3 2026) against $190K for aTYR Pharma (Q3 2025).
More: Beam Therapeutics earnings · how Beam Therapeutics makes money · aTYR Pharma earnings · how aTYR Pharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Nov 6, 2025). Fiscal quarters can end on different dates. Not investment advice.